

# Relationships between lifestyle patterns and cardio-renal-metabolic parameters in patients with type 2 diabetes mellitus: A cross-sectional study

|                              |   |
|------------------------------|---|
| 著者別名                         | 五所 正彦   |
| journal or publication title | PLOS ONE  |
| volume                       | 12  |
| number                       | 3   |
| page range                   | e0173540  |
| year                         | 2017-03   |
| 権利                           | (C) 2017 Ogihara et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| URL                          | <a href="http://hdl.handle.net/2241/00145795">http://hdl.handle.net/2241/00145795</a>   |

doi: 10.1371/journal.pone.0173540

RESEARCH ARTICLE

# Relationships between lifestyle patterns and cardio-renal-metabolic parameters in patients with type 2 diabetes mellitus: A cross-sectional study

Takeshi Ogihara<sup>1</sup>, Tomoya Mita<sup>1,2\*</sup>, Yusuke Osonoi<sup>1</sup>, Takeshi Osonoi<sup>3</sup>, Miyoko Saito<sup>3</sup>, Atsuko Tamasawa<sup>3</sup>, Shiho Nakayama<sup>1</sup>, Yuki Someya<sup>1</sup>, Hidenori Ishida<sup>3</sup>, Masahiko Gosho<sup>4</sup>, Akio Kanazawa<sup>1,2</sup>, Hirotaka Watada<sup>1,2,5,6</sup>

**1** Department of Metabolism & Endocrinology, Tokyo, Japan, **2** Center for Therapeutic Innovations in Diabetes, Tokyo, Japan, **3** Naka Memorial Clinic, Naka City, Ibaraki, Japan, **4** Department of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, **5** Center for Molecular Diabetology, Tokyo, Japan, **6** Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan

\* [tom-m@juntendo.ac.jp](mailto:tom-m@juntendo.ac.jp)



**OPEN ACCESS**

**Citation:** Ogihara T, Mita T, Osonoi Y, Osonoi T, Saito M, Tamasawa A, et al. (2017) Relationships between lifestyle patterns and cardio-renal-metabolic parameters in patients with type 2 diabetes mellitus: A cross-sectional study. *PLoS ONE* 12(3): e0173540. doi:10.1371/journal.pone.0173540

**Editor:** Cheng Hu, Shanghai Diabetes Institute, CHINA

**Received:** December 24, 2016

**Accepted:** February 22, 2017

**Published:** March 8, 2017

**Copyright:** © 2017 Ogihara et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper.

**Funding:** This study was supported by research grant from Manpei Suzuki Diabetes Foundation (to T.M., Number 26-76). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** H.W. has received lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Ono Pharmaceutical Co., Novo Nordisk Pharma,

## Abstract

### Introduction

While individuals tend to show accumulation of certain lifestyle patterns, the effect of such patterns in real daily life on cardio-renal—metabolic parameters remains largely unknown. This study aimed to assess clustering of lifestyle patterns and investigate the relationships between such patterns and cardio-renal-metabolic parameters.

### Participants and methods

The study participants were 726 Japanese type 2 diabetes mellitus (T2DM) outpatients free of history of cardiovascular diseases. The relationship between lifestyle patterns and cardio-renal-metabolic parameters was investigated by linear and logistic regression analyses.

### Results

Factor analysis identified three lifestyle patterns. Subjects characterized by evening type, poor sleep quality and depressive status (type 1 pattern) had high levels of HbA1c, alanine aminotransferase and albuminuria. Subjects characterized by high consumption of food, alcohol and cigarettes (type 2 pattern) had high levels of  $\gamma$ -glutamyl transpeptidase, triglycerides, HDL-cholesterol, blood pressure, and brachial-ankle pulse wave velocity. Subjects characterized by high physical activity (type 3 pattern) had low uric acid and mild elevation of alanine aminotransferase and aspartate aminotransferase. In multivariate regression analysis adjusted by age, gender and BMI, type 1 pattern was associated with higher HbA1c levels, systolic BP and brachial-ankle pulse wave velocity. Type 2 pattern was associated with higher HDL-cholesterol levels, triglycerides, aspartate aminotransferase,  $\gamma$ -glutamyl transpeptidase levels, and diastolic BP.

Novartis Pharmaceuticals, Eli Lilly, Sanwakagaku Kenkyusho, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD, Dainippon Sumitomo Pharm., Kowa Co. and research funds from Boehringer Ingelheim, Pfizer, Mochida Pharmaceutical Co., Sanofi-Aventis, Novo Nordisk Pharma, Novartis Pharmaceuticals, Sanwakagaku Kenkyusho, Terumo Corp. Eli Lilly, Mitsubishi Tanabe Pharma, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD, Shionogi, Pharma, Dainippon Sumitomo Pharma, Kissei Pharma, and Astrazeneca. Other authors have no conflicting interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; BaPWV, brachial-ankle pulse wave velocity; BDHQ, brief, self-administered diet history questionnaire; BDI, Beck Depression inventory; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate;  $\gamma$ -GTP,  $\gamma$ -glutamyl transpeptidase; HDL, high-density lipoprotein-cholesterol; IPAQ, International Physical Activity Questionnaire; MEQ, morningness-eveningness questionnaire; NGSP, National Glycohemoglobin Standardization Program; PSQI, Pittsburg Sleep Quality Index; T2DM, Type 2 diabetes mellitus; UAE, Urinary albumin excretion.

## Conclusions

The study identified three lifestyle patterns that were associated with distinct cardio-metabolic-renal parameters in T2DM patients.

## Trial registration

[UMIN000010932](https://doi.org/10.1186/1745-6215-10932)

## Introduction

The incident of type 2 diabetes mellitus (T2DM) is related to numerous lifestyle problems. Furthermore, the incidence of cardiovascular disease (CVD) and diabetes related microvascular events is strongly related with lifestyle factors in patients with T2DM [1,2]. Lifestyle modifications such as a reduction in energy intake and an increase in physical activity can reduce the onset of T2DM [3] in non-T2DM population and the development of CVD in T2DM patients [4,5]. On the other hand, the reported effects of these interventions on the risks were very modest. Furthermore, a recent clinical trial that focused on the control of energy intake and increased physical activity in obese patients with T2DM showed no effect for lifestyle intervention on CVD [6]. In this regard, much attention should be paid to lifestyles other than diet and physical activity as lifestyle problems that could affect future CVD.

Recent studies have demonstrated the importance of sleep duration and/or quality as lifestyle factors, based on findings confirming the pathological roles of these factors in the onset of T2DM [7] and CVD [8]. Other studies reported that both sleep duration and/or quality can affect cardiovascular risk factors in T2DM patients [9–11].

Morningness-eveningness reflects the timing of the sleep-wake pattern and different aspects of sleep duration and/or quality, which are quite variable among individuals. In individuals of the evening type, social rhythms do not synchronize with the circadian clock. Previous studies demonstrated that evening type individuals tend to have unhealthy eating habits, behavioral health problems, and sleep complains more than morning type subjects [12,13]. More recently, we found inadequate glycemic control in evening type patients with T2DM [14] [15]. These findings suggest that evening type individuals potentially have impaired metabolism by abnormal circadian rhythm.

The prevalence of depression is reportedly higher in T2DM patients than non-T2DM [16]. Given that T2DM-related depression is related to poor glycemic control [17] and micro- and macro-vascular complications [18], partly due to increased counter-regulatory hormones [19], the depression status may be an important risk factor for defective glycemic control and T2DM-related complications in patients with T2DM.

In daily life, people have variable lifestyle patterns that can influence their cardio-renal-metabolic parameters. In this regard, it is conceivable that certain specific lifestyle patterns tend to accumulate in individual patients with T2DM. If we can classify the patients according to such accumulated lifestyle patterns, it would be useful to design treatment strategies tailored to the individual patients with T2DM. The aim of the present study was to explore possible classification of patients with T2DM free of history of CVD, according to clustering of lifestyle factors and mental status by factor analysis. We then investigated the relationships between each cluster of lifestyle factors (e.g., circadian rhythm, habitual sleep, mental state, diet, alcohol consumption, cigarettes consumption, physical activity) and cardio-renal—metabolic parameters,

including brachial-ankle pulse wave velocity (baPWV), which is considered a useful predictor of CVD [20].

## Materials and methods

### Patients

The subjects of this cohort study were recruited from the Diabetes Outpatient Clinic of Juntendo University, (Tokyo, Japan) Naka Memorial Clinic (Naka, Japan) or Secomedic Hospital (Funabashi, Japan) as previously described [15] [21] [22]. T2DM patients who were between 25 and 70 years of age without history of apparent CVD were included.

A total of 1,032 consecutive subjects were screened as previously described [15]. Briefly, among them, 906 patients who met the above eligibility criteria were invited to participate in the present study. After providing information on the purpose and procedures of the study, 736 patients with T2DM were recruited. The study was approved by the Institutional Review Board of Juntendo University Hospital and conducted in accordance with the principles described in the Declaration of Helsinki. All patients provided written informed consent prior to participation. The study has been registered on the University Hospital Medical Information Network Clinical Trials Registry (UMIN000010932).

### Questionnaire survey

Questionnaire survey was conducted using valid and reliable self-administered questionnaires described previously [15]. Briefly, we used the Morning Evening Questionnaire (MEQ) [23], which is a self-assessment questionnaire developed primarily for screening candidates for sleep-related experiments to evaluate morningness and eveningness in individuals. A high MEQ score represents morning type.

The Pittsburgh Sleep Quality Index (PSQI) [24] is a self-administered questionnaire designed to evaluate sleep quality and consists of 18 items that in turn are comprised of 7 components, with each weighted equally on a 0–3 scale to be summed to yield the global PSQI score ranging from 0 to 21, where the higher the scores, the worse the sleep quality.

The participating patients also completed the BDI (Beck Depression inventory)-II, which is a 21-item questionnaire [25]. A high BDI score represents depressive state.

Dietary habits during the preceding month were assessed with the validated, Brief, self-administered Diet History Questionnaire (BDHQ). The BDHQ is a 4-page structured questionnaire that asks about consumption frequency of selected foods to estimate the dietary intake of 56 food and beverage items with specified serving size described in terms of consumption in general Japanese populations [26].

Physical activity level was assessed with the International Physical Activity Questionnaire (IPAQ) that comprises four simple questions on physical activity [27]. The IPAQ results are expressed as metabolic equivalent scores (METs·hour·week<sup>-1</sup>).

Workers were defined as full-time employees or shift workers by a question in the questionnaire as described previously [15]. The subjects were also divided into non-smokers, former smokers or current smokers, as described previously [15]. Estimation of the total number of cigarettes was calculated by cigarettes smoked per day times smoking duration (years).

### Biochemical tests

Blood samples were obtained at visits after overnight fast. Liver and renal function tests, lipids, HbA1c, and glucose, (National Glycohemoglobin Standardization Program) were measured with standard techniques. Urinary albumin excretion (UAE) was measured by latex

agglutination assay using a spot urine sample. The estimated glomerular filtration rate (eGFR) was calculated by the formula:  $eGFR \text{ (ml/min per } 1.73 \text{ m}^2) = 194 \times \text{Age}^{-0.287} \times \text{serum creatinine}^{-0.1094}$  ( $\times 0.739$  for females) [28].

## Measurement of baPWV

baPWV was measured using an automatic waveform analyzer (BP-203RPE; Colin Medical Technology, Komaki, Japan), as described previously [15] [29]. All scans were automatically conducted by well-trained investigators who were blinded to the clinical information.

## Statistical analysis

Results are presented as mean $\pm$ SD or median (interquartile range: 25% to 75%) for continuous variables or number (proportion) of patients for categorical variables. Some parameters were logarithmically transformed to approximate a normal distribution. We used factor analysis with oblique promax rotation to reduce the complexity of lifestyle patterns of patients with T2DM by morningness-eveningness, quality of sleep including sleep duration, depressive status, energy intake, alcohol consumption, cigarettes smoking, and physical activity. Factors with an eigenvalue  $>1$  were retained. Individual metabolites with a factor loading of  $>|0.3|$  are reported as composing that factor for simplicity. The factor scores for each lifestyle pattern and for each subject were calculated by summing each lifestyle score weighted by their factor loadings. The estimated factor scores were categorized into quintiles. Trend association across the quintile was evaluated by linear regression analysis for continuous variables and logistic regression analysis for categorical variables. We developed three models to evaluate the trend. The first model was unadjusted, second model was adjusted for age and gender, and third model adjusted for age, gender, and body mass index (BMI). The model for eGFR was only adjusted for BMI. Multivariate regression analysis adjusting for age, gender and BMI was performed to investigate what types of lifestyle patterns identified in this study were related with cardio-renal-metabolic parameters. Statistical tests were two-sided with 5% significant level. All analyses were performed using the SAS software version 9.3 (SAS Institute, Cary, North Carolina).

## Results

Ten patients were thus excluded from analysis because they did not complete the questionnaires among 736 patients. The characteristics of 726 subjects were shown in Table 1. The mean age was  $57.8 \pm 8.6$  years, 62.9% male and HbA1c was  $7.0 \pm 1.0\%$ . Glucose and lipid metabolisms and BP were well controlled in those subjects.

Factor analysis with oblique promax rotation identified three life style patterns (Table 2). Factor 1 seemed to be characterized by morningness-eveningness, sleep quality and depressive status (Type 1 pattern), Factor 2 by consumption of food, alcohol and cigarettes (Type 2 pattern), and Factor 3 by physical activity (Type 3 Pattern).

The characteristics across quintile of lifestyle pattern on each type are shown in Tables 3–5. Table 3 shows the characteristics of the study subjects based on the quintiles of type 1 pattern scores. Subjects with a higher score for this pattern represent more evening type, poor sleep quality, and depressive status. They tended to be young, female, and worker or shift worker in the unadjusted model. Also, they tended to go to bed late, wake up late and sleep for shorter time. In addition, those patients tended to have less frequently have breakfast, and have late dinner, and late breakfast, frequently have late evening snacks, and consumption of large amount of food. These findings suggest they seem to consume greater percentage of their daily energy at late time. In addition, they has significantly higher BMI, alanine aminotransferase

**Table 1. Patients characteristics (n = 726).**

| <b>Demographic data</b>                |               |
|--|---------------|
| Age (years)                            | 57.8±8.6      |
| Gender (male)                          | 456 (62.9)    |
| Estimated duration of diabetes (years) | 9.9±7.2       |
| Body mass index (kg/m <sup>2</sup> )   | 24.6±4.1      |
| HbA1c (%)                              | 7.0±1.0       |
| HbA1c (mmol/mol)                       | 52.5±10.8     |
| Fasting blood glucose (mg/dl)          | 134±31        |
| Systolic blood pressure (mmHg)         | 127±14        |
| Diastolic blood pressure (mmHg)        | 77±11         |
| Total cholesterol (mg/dL)              | 185±28        |
| HDL-cholesterol (mg/dL)                | 59±14         |
| Triglyceride (mg/dL)                   | 100 [70, 152] |
| AST (U/L)                              | 21 [18, 27]   |
| ALT (U/L)                              | 22 [16, 33]   |
| γ-GTP (U/L)                            | 25 [17, 39]   |
| Uric Acid (mg/dl)                      | 5.5 ± 1.2     |
| eGFR (ml/min/ 1.73 m <sup>2</sup> )    | 78 ± 18       |
| UAE (mg/g creatinine)                  | 10 [6, 23]    |
| baPWV (cm/s)                           | 1543± 279     |
| Morningness-Eveningness Questionnaire  | 57.4 ± 7.3    |
| Pittsburg Sleep Quality Index          | 5.1 ± 3.0     |
| Beck Depression inventory -II          | 9.9 ± 7.6     |
| Energy intake (kcal/day)               | 1713±582      |
| Physical activity (Mets-h/week)        | 42.8±70.5     |
| Sleep duration (hours)                 | 6.4±1.2       |
| Number of cigarettes                   | 335±458       |
| Current smoker (yes)                   | 174 (24.0)    |
| Alcohol (g/day)                        | 12.3±21.5     |
| On treatment for (n/%)                 |               |
| Diabetes                               | 620 (85.5)    |
| Hypertension                           | 346 (47.7)    |
| Hyperlipidemia                         | 442 (61.0)    |

Data are mean±SD or number (proportion) of patients. ALT: alanine aminotransferase; AST: aspartate aminotransferase; baPWV: brachial-ankle pulse wave velocity; eGFR: estimated glomerular filtration rate, HDL-C: high-density lipoprotein-cholesterol, UAE, urinary albumin excretion, γ-GTP, γ-glutamyl transpeptidase.

doi:10.1371/journal.pone.0173540.t001

**Table 2. Life style items and factor analysis with oblique promax rotation.**

| <b>Components and item labels</b>             | <b>Factor 1</b> | <b>Factor 2</b> | <b>Factor 3</b> |
|---|-----------------|-----------------|-----------------|
| Morningness Eveningness Questionnaire         | <b>-0.62</b>    | 0.12            | 0.21            |
| Pittsburg Sleep Quality Index                 | <b>0.78</b>     | 0.02            | 0.08            |
| Beck Depression inventory                     | <b>0.71</b>     | 0.06            | 0.01            |
| Energy intake                                 | 0.12            | <b>0.64</b>     | 0.29            |
| Smoking                                       | -0.05           | <b>0.65</b>     | -0.22           |
| Alcohol intake                                | -0.05           | <b>0.81</b>     | -0.04           |
| International Physical Activity Questionnaire | -0.05           | -0.06           | <b>0.93</b>     |
| Contribution                                  | 22%             | 21%             | 14%             |

doi:10.1371/journal.pone.0173540.t002

**Table 3. Characteristics according to quintile categories of type 1 life style pattern score.**

| Variable                               | Quintile 1             | Quintile 2             | Quintile 3             | Quintile 4             | Quintile 5             | Est1   | Est2   | Est3   |
|--|------------------------|------------------------|------------------------|------------------------|------------------------|--------|--------|--------|
| MEQ                                    | 64.6 ± 4.9             | 60.2 ± 4.9             | 56.5 ± 5.7             | 54.4 ± 6.4             | 51.4 ± 6.4             | -3.22¶ | -2.96¶ | -2.95¶ |
| PSQI                                   | 2.6 ± 1.3              | 3.7 ± 1.4              | 4.6 ± 1.7              | 5.9 ± 2.1              | 8.7 ± 3.6              | 1.45¶  | 1.49¶  | 1.48¶  |
| BDI                                    | 3.6 ± 3.6              | 6.6 ± 4.6              | 8.3 ± 4.8              | 11.9 ± 5.7             | 19.0 ± 8.1             | 3.61¶  | 3.72¶  | 3.72¶  |
| Energy intake (kcal/day)               | 1609 ± 463             | 1709 ± 535             | 1650 ± 567             | 1811 ± 559             | 1782 ± 733             | 44.6†  | 68.7¶  | 68.6¶  |
| Smoking (number)                       | 388 ± 466              | 318 ± 453              | 357 ± 519              | 328 ± 460              | 279 ± 379              | -20.8  | 12.5   | 11.9   |
| Alcohol (g/day)                        | 16.2 ± 23.2            | 11.8 ± 19.6            | 9.6 ± 21.6             | 13.0 ± 21.3            | 10.5 ± 21.3            | -1.04  | -0.01  | -0.06  |
| Physical activity (Mets·h/week)        | 47.5 ± 60.8            | 38.2 ± 56.4            | 45.7 ± 77.0            | 43.0 ± 81.6            | 40.1 ± 74.8            | -1.00  | -0.02  | 0.27   |
| Age (years)                            | 61.2 ± 6.3             | 59.8 ± 7.6             | 56.9 ± 8.8             | 56.1 ± 9.3             | 54.8 ± 9.0             | -1.65¶ | -      | -      |
| Gender (male)                          | 107 (74.3)             | 95 (66.0)              | 83 (57.6)              | 93 (64.6)              | 73 (50.7)              | -0.21¶ | -      | -      |
| Body mass index (kg/m <sup>2</sup> )   | 23.9 ± 3.5             | 23.9 ± 3.7             | 24.8 ± 4.2             | 24.8 ± 3.8             | 25.8 ± 4.7             | 0.46¶  | 0.18   | -      |
| Estimated duration of diabetes (years) | 10.3 ± 7.4             | 9.4 ± 6.3              | 8.6 ± 7.8              | 10.8 ± 7.6             | 10.4 ± 6.7             | 0.17   | 0.58   | 0.62   |
| Anti-diabetes medications (yes)        | 123(85.4)              | 121(84.0)              | 121(84.0)              | 126(87.5)              | 125(86.8)              | 0.05   | 0.07   | 0.07   |
| Anti-hypertensives (yes)               | 67(46.5)               | 72(50.0)               | 59(41.0)               | 73(50.7)               | 73(50.7)               | 0.04   | 0.08   | 0.06   |
| Lipid-lowering agents (yes)            | 86(59.7)               | 90(62.5)               | 90(62.5)               | 86(59.7)               | 88(61.1)               | 0.00   | 0.01   | 0.00   |
| Working (yes)                          | 96(66.7)               | 101(70.1)              | 106(73.6)              | 110(76.4)              | 116(80.6)              | 0.18†  | 0.15*  | 0.15*  |
| Shift worker (yes)                     | 9(6.3)                 | 16(11.1)               | 13(9.0)                | 19(13.2)               | 20(13.9)               | 0.18*  | 0.07   | 0.08   |
| Sleep duration (hours)                 | 7.1±1.1                | 6.7±0.9                | 6.4±1.0                | 6.2±1.2                | 5.9±1.2                | 0.07*  | 0.02   | 0.02   |
| Wake time, A.M.                        | 5:30[5:00,6:00]        | 6:00[5:18,6:30]        | 6:00[5:30,6:30]        | 6:00[5:30,6:30]        | 6:18[5:30,7:00]        | -0.30¶ | -0.27¶ | -0.27¶ |
| Bed time, P.M.                         | 22:15<br>[21:30,23:00] | 23:00<br>[22:00,23:30] | 23:08<br>[22:20,24:00] | 23:15<br>[22:30,24:00] | 23:50<br>[23:00,24:30] | 0.19¶  | 0.18¶  | 0.18¶  |
| Breakfast time, A.M.                   | 7:00[6:15,7:18]        | 7:00[6:30,7:30]        | 7:00[6:30,7:30]        | 7:00[6:30,7:30]        | 7:20[6:40,8:00]        | 0.33¶  | 0.24¶  | 0.24¶  |
| Dinner time, P.M.                      | 19:00<br>[18:30,19:30] | 19:00<br>[18:30,19:30] | 19:00<br>[19:00,20:00] | 19:00<br>[18:30,20:00] | 19:30<br>[19:00,20:00] | 0.14¶  | 0.13¶  | 0.13¶  |
| Number of breakfasts (/week)           | 6.9±0.6                | 6.8±0.8                | 6.7±0.9                | 6.5±1.4                | 6.0±1.9                | 0.18¶  | 0.14¶  | 0.13¶  |
| Late evening snack (yes)               | 38 (26.4)              | 50 (34.7)              | 68 (47.2)              | 68 (47.2)              | 64 (44.4)              | 0.21¶  | 0.22¶  | 0.22¶  |
| AST (U/L)                              | 21 [18,27]             | 21 [18,27]             | 22 [17,25]             | 21 [18,26]             | 21 [18,28]             | 0.00   | 0.00   | 0.00   |
| ALT (U/L)                              | 21 [16,31]             | 23 [16,35]             | 22 [16,32]             | 24 [17,34]             | 24 [16,38]             | 0.04¶  | 0.03*  | 0.02   |
| γ-GTP (U/L)                            | 25 [17,36]             | 24 [17,35]             | 25 [18,40]             | 27 [18,46]             | 22 [15,42]             | 0.02   | 0.02   | 0.01   |
| Uric Acid (mg/dl)                      | 5.5 ± 1.2              | 5.5 ± 1.2              | 5.5 ± 1.2              | 5.5 ± 1.3              | 5.4 ± 1.3              | -0.01  | 0.00   | -0.01  |
| eGFR (ml/min/ 1.73 m <sup>2</sup> )    | 76 ± 18                | 78 ± 18                | 79 ± 17                | 77 ± 18                | 80 ± 17                | 0.72   | -      | 0.51   |
| Total cholesterol (mg/dl)              | 186 ± 25               | 185 ± 31               | 186 ± 30               | 183 ± 26               | 187 ± 27               | 0.03   | -0.45  | -0.55  |
| HDL-C (mg/dl)                          | 62 ± 15                | 59 ± 15                | 59 ± 14                | 57 ± 14                | 59 ± 13                | -0.59  | -0.46  | -0.30  |
| Triglycerides (mg/dl)                  | 94 [66,146]            | 98 [67,145]            | 96 [69,139]            | 112 [77,164]           | 104 [73,152]           | 0.03*  | 0.02   | 0.01   |
| Fasting blood glucose (mg/dl)          | 127 ± 28               | 134 ± 32               | 131 ± 27               | 136 ± 32               | 141 ± 34               | 2.90¶  | 2.29†  | 2.21*  |
| HbA1c (%)                              | 6.7 ± 0.8              | 6.9 ± 1.0              | 6.9 ± 1.0              | 7.1 ± 1.1              | 7.1 ± 1.1              | 0.11¶  | 0.07†  | 0.07*  |
| HbA1c (mmol/mol)                       | 49.5±8.3               | 52.4±10.8              | 52.2±10.5              | 54.0±12.0              | 54.6±11.6              |        |        |        |
| Systolic BP (mmHg)                     | 127 ± 15               | 125 ± 14               | 125 ± 14               | 127 ± 13               | 129 ± 15               | 0.61   | 0.71   | 0.52   |
| Diastolic BP (mmHg)                    | 77 ± 13                | 76 ± 10                | 76 ± 10                | 78 ± 11                | 78 ± 12                | 0.36   | 0.08   | -0.04  |
| UAE (mg/g creatinine)                  | 10 [6, 21]             | 9[6, 15]               | 10 [6, 24]             | 11 [6, 35]             | 11 [6, 26]             | 0.06   | 0.08*  | 0.07   |

(Continued)

**Table 3.** (Continued)

| Variable     | Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | Est1   | Est2 | Est3 |
|--------------|------------|------------|------------|------------|------------|--------|------|------|
| baPWV (cm/s) | 1582 ± 304 | 1563 ± 302 | 1514 ± 274 | 1540 ± 266 | 1517 ± 246 | -15.31 | 9.56 | 9.90 |

Data are mean±SD, median [range: 25% to 75%] or number of subjects (proportion) before adjustment. Est1: Trend estimation for linear trends across quintiles is based on linear regression analysis for continuous variables or logistic regression analysis for categorical variables. Est2: Trend estimation for linear trends across quintiles is based on linear regression analysis for continuous variables or logistic regression analysis for categorical variables adjusted for age and gender. Est3: Trend estimation for linear trends across quintiles is based on linear regression analysis for continuous variables or logistic regression analysis for categorical variables adjusted for age, gender and BMI. eGFR is adjusted for BMI.

\*P<0.05,

†P<0.01,

‡P<0.001 for testing the trend.

For trend test, log-transformed AST, ALT, γ-GTP, UAE, and TG. ALT: alanine aminotransferase; AST: aspartate aminotransferase; baPWV: brachial-ankle pulse wave velocity; BP: blood pressure; BDI: Beck Depression inventory, eGFR: estimated glomerular filtration rate, Est, estimation of regression coefficient, HDL-C: high-density lipoprotein-cholesterol, MEQ: morningness-eveningness questionnaire, PSQI: Pittsburg Sleep Quality Index, UAE, urinary albumin excretion, γ-GTP, γ-glutamyl transpeptidase.

doi:10.1371/journal.pone.0173540.t003

(ALT) levels, HbA1c levels and fasting blood glucose levels in the unadjusted model. Furthermore, fasting blood glucose and HbA1c levels were significantly higher in patients with higher scores of type 1 pattern even in the model adjusted for age, gender and BMI. Also, ALT and UAE were higher in the adjusted model by age and gender.

Table 4 lists the characteristics of the study subjects based on the quintiles of type 2 pattern scores. Subjects with a higher score of this pattern tended to be old, males, current smokers, and workers or shift workers in the unadjusted model. Furthermore, these patients tended to go to bed early, wake up early and eat breakfast early. Accordingly, they tended to be morning type, but less frequently had breakfast. With regard to the cardio-metabolic parameters, patients with higher score of type 2 pattern showed significantly higher aspartate aminotransferase (AST) levels, γ-glutamyl transpeptidase (γ-GTP) levels, uric acid and triglycerides. These data reflect patterns of alcoholic liver dysfunction, while there was no significant difference in BMI among the groups. On the other hand, HbA1c levels were significantly lower in these patients in the unadjusted model, but this finding was not observed in the adjusted model. The use of lipid-lowering medications, especially statin but not fibrate (data not shown), was lower in patients with a higher score of type 2 pattern. With regard to BP, these patients had high systolic and diastolic BP despite high use of antihypertensive drugs. Also, baPWV was significantly higher in those patients. According to the adjusted models by age and gender and by age, gender, and BMI, subjects with a higher score for this pattern had higher γ-GTP, triglyceride, HDL-cholesterol levels, systolic and diastolic BP, and baPWV.

Table 5 shows the characteristics of the study subjects according to the quintiles of type 3 pattern scores. Subjects with a higher score for this pattern were old, non-smokers, shift workers, and morning type. These patients are likely to have low BMI despite the large amount of food intake. They tended to go to bed early, wake up early, sleep for short duration and have early dinner. Patients with a higher score of type 3 pattern showed significantly lower uric acid, triglyceride and diastolic BP, and higher HDL-cholesterol. However, these subjects only had lower uric acid levels, rather higher AST and ALT, in the adjusted models by age and gender and by age, gender and BMI. They also had higher AST and ALT, and were less likely to use antihypertensive medication, in the adjusted model by age and gender.

Next, we performed a multivariate regression analysis to investigate whether three types of lifestyle patterns identified in this study were related with cardio-renal-metabolic parameters



**Table 4. Characteristics according to quintile categories of type 2 pattern score.**

| Variable                               | Quintile 1             | Quintile 2             | Quintile 3             | Quintile 4             | Quintile 5             | Est1   | Est2    | Est3   |
|--|------------------------|------------------------|------------------------|------------------------|------------------------|--------|---------|--------|
| MEQ                                    | 55.3 ± 7.2             | 57.6 ± 7.0             | 57.0 ± 7.4             | 57.7 ± 6.4             | 59.6 ± 7.9             | 0.87†  | 0.62*   | 0.63*  |
| PSQI                                   | 5.1 ± 3.4              | 5.1 ± 2.9              | 4.9 ± 2.5              | 5.6 ± 3.5              | 4.9 ± 2.9              | 0.00*  | 0.24*   | 0.23*  |
| BDI                                    | 9.1 ± 7.9              | 10.6 ± 8.1             | 9.8 ± 7.4              | 9.6 ± 7.8              | 10.3 ± 7.2             | 0.12   | 0.75†   | 0.75†  |
| Energy intake (kcal/day)               | 1144 ± 241             | 1531 ± 272             | 1711 ± 385             | 1913 ± 480             | 2262 ± 707             | 261.7¶ | 302.61¶ | 302.9¶ |
| Smoking (number)                       | 25 ± 79                | 88 ± 186               | 284 ± 314              | 446 ± 346              | 827 ± 615              | 196.3¶ | 168.3¶  | 168.1¶ |
| Current smoker (yes)                   | 11 (7.6)               | 19 (13.2)              | 39 (27.1)              | 51 (35.4)              | 50 (34.7)              | 0.45¶  | 0.38¶   | 0.39¶  |
| Alcohol (g/day)                        | 0.6 ± 2.1              | 0.8 ± 2.3              | 3.9 ± 6.5              | 12.4 ± 13.0            | 43.3 ± 28.1            | 9.71¶  | 9.62¶   | 9.61¶  |
| Physical activity (Mets·h/week)        | 41.4 ± 68.1            | 38.5 ± 61.3            | 47.3 ± 68.9            | 40.2 ± 65.5            | 47.2 ± 87.1            | 1.31   | 0.37    | 0.60   |
| Age (years)                            | 56.7 ± 9.5             | 57.5 ± 8.5             | 57.3 ± 8.5             | 57.3 ± 8.7             | 59.9 ± 7.3             | 0.62†  | -       | -      |
| Gender (male)                          | 35 (24.3)              | 63 (43.8)              | 90 (62.5)              | 126 (87.5)             | 137 (95.1)             | 1.01¶  | -       | -      |
| Body mass index (kg/m <sup>2</sup> )   | 24.6 ± 4.1             | 24.9 ± 4.0             | 24.4 ± 4.4             | 24.9 ± 4.1             | 24.4 ± 3.6             | -0.04  | 0.14    | -      |
| Estimated duration of diabetes (years) | 9.5±8.3                | 10.2±6.8               | 9.3±6.3                | 9.8±6.9                | 10.8±7.6               | 0.24   | 0.13    | 0.16   |
| Anti-diabetes medications (yes)        | 127(88.2)              | 124(86.1)              | 119(82.6)              | 122(84.7)              | 124(86.1)              | -0.04  | -0.10   | -0.09  |
| Anti-hypertensives (yes)               | 68(47.2)               | 60(41.7)               | 56(38.9)               | 70(48.6)               | 90(62.5)               | 0.15†  | 0.17†   | 0.16*  |
| Lipid-lowering agents (yes)            | 97(67.4)               | 96(66.7)               | 91(63.2)               | 83(57.6)               | 73(50.7)               | -0.18† | -0.15*  | -0.16* |
| Working (yes)                          | 100(69.4)              | 90(62.5)               | 108(75.0)              | 117(81.3)              | 114(79.2)              | 0.20†  | 0.04    | 0.05   |
| Shift worker (yes)                     | 22(15.3)               | 13(9.0)                | 18(12.5)               | 19(13.2)               | 5(3.5)                 | -0.21* | -0.03   | -0.02  |
| Sleep duration (hours)                 | 6.4±1.1                | 6.4±1.1                | 6.4±1.1                | 6.4±1.0                | 6.7±1.3                | 0.07*  | 0.01    | 0.01   |
| Wake time, A.M.                        | 6:00[5:30,7:00]        | 6:00[5:25,6:30]        | 6:00[5:30,6:30]        | 6:00[5:30,6:30]        | 6:00[5:00,6:30]        | -0.11† | -0.15†  | -0.16¶ |
| Bed time, P.M.                         | 23:00<br>[22:30,24:00] | 23:00<br>[22:00,24:00] | 23:00<br>[22:30,23:50] | 23:00<br>[22:00,23:50] | 22:30<br>[21:30,23:30] | -0.12† | -0.04   | -0.04  |
| Breakfast time, A.M.                   | 7:00[6:30,7:45]        | 7:00[6:30,7:40]        | 7:00[6:25,7:30]        | 7:00[6:30,7:30]        | 7:00[6:30,7:30]        | -0.08† | -0.02   | -0.02  |
| Dinner time, P.M.                      | 19:20<br>[18:30,20:00] | 19:00<br>[18:30,19:30] | 19:00<br>[18:30,19:40] | 19:00<br>[18:30,20:00] | 19:00<br>[18:30,20:00] | 0.00   | -0.01   | -0.01  |
| Number of breakfasts (/week)           | 6.6±1.1                | 6.7±1.0                | 6.6±1.3                | 6.7±1.1                | 6.4±1.7                | -0.05  | -0.05   | -0.04  |
| Late evening snack (yes)               | 47(32.6)               | 64(44.4)               | 73(50.7)               | 60(41.7)               | 44(30.6)               | -0.03  | 0.04    | 0.04   |
| AST (U/L)                              | 21 [18,26]             | 21 [18,26]             | 20 [17,25]             | 22 [17,28]             | 23 [20,29]             | 0.02*  | 0.02    | 0.02   |
| ALT (U/L)                              | 20 [15,31]             | 21 [16,34]             | 22 [16,29]             | 25 [17,35]             | 24 [17,34]             | 0.02   | 0.02    | 0.02   |
| γ-GTP (U/L)                            | 21 [15,32]             | 24 [16,35]             | 22 [15,36]             | 27 [20,44]             | 35 [22,57]             | 0.11¶  | 0.08¶   | 0.07¶  |
| Uric Acid (mg/dl)                      | 5.2 ± 1.2              | 5.3 ± 1.2              | 5.3 ± 1.2              | 5.8 ± 1.3              | 5.9 ± 1.1              | 0.20¶  | 0.04    | 0.03   |
| eGFR (ml/min/ 1.73 m <sup>2</sup> )    | 79 ± 19                | 77 ± 18                | 80 ± 20                | 77 ± 16                | 77 ± 17                | -0.42  | -       | -0.40  |
| Total cholesterol (mg/dl)              | 187 ± 27               | 188 ± 28               | 185 ± 30               | 184 ± 28               | 182 ± 26               | -1.29  | 0.81    | 0.73   |
| HDL-C (mg/dl)                          | 62 ± 13                | 59 ± 14                | 58 ± 15                | 57 ± 14                | 61 ± 14                | -0.25  | 1.11†   | 1.24†  |
| Triglycerides (mg/dl)                  | 94 [67, 130]           | 99 [69, 146]           | 104[74, 139]           | 108 [72, 157]          | 117 [70, 165]          | 0.04†  | 0.05†   | 0.04*  |
| Fasting blood glucose (mg/dl)          | 134 ± 33               | 135 ± 35               | 128 ± 23               | 134 ± 30               | 138 ± 32               | 0.84   | 1.04    | 0.98   |
| HbA1c (%)                              | 7.0 ± 1.1              | 7.1 ± 1.1              | 6.9 ± 0.8              | 7.0 ± 1.1              | 6.8 ± 0.9              | -0.06* | -0.02   | -0.03  |
| HbA1c (mmol/mol)                       | 53.5±11.7              | 53.9±12.1              | 51.7±8.7               | 52.8±11.5              | 50.8±9.5               |        |         |        |
| Systolic BP (mmHg)                     | 128 ± 14               | 124 ± 14               | 124 ± 14               | 128 ± 15               | 129 ± 14               | 0.68   | 1.28†   | 1.13†  |
| Diastolic BP (mmHg)                    | 77 ± 9                 | 74 ± 9                 | 75 ± 11                | 79 ± 14                | 80 ± 10                | 1.11¶  | 0.83*   | 0.74*  |
| UAE (mg/g creatinine)                  | 11 [7, 25]             | 11 [6, 21]             | 8 [5, 15]              | 9 [5, 21]              | 13 [7, 35]             | 0.03   | 0.07    | 0.06   |

(Continued)

Table 4. (Continued)

| Variable     | Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | Est1             | Est2  | Est3  |
|--------------|------------|------------|------------|------------|------------|------------------|-------|-------|
| baPWV (cm/s) | 1490 ± 245 | 1530 ± 281 | 1519 ± 271 | 1566 ± 272 | 1611 ± 313 | 278 <sup>†</sup> | 16.9* | 17.1* |

Data are mean±SD, median [range: 25% to 75%] or number of subjects (proportion) before adjustment. Est1: Trend estimation for linear trends across quintiles is based on linear regression analysis for continuous variables or logistic regression analysis for categorical variables. Est2: Trend estimation for linear trends across quintiles is based on linear regression analysis for continuous variables or logistic regression analysis for categorical variables adjusted for age and gender. Est3: Trend estimation for linear trends across quintiles is based on linear regression analysis for continuous variables or logistic regression analysis for categorical variables adjusted for age, gender and BMI. eGFR is adjusted for BMI.

\*P<0.05,

<sup>†</sup>P<0.01,

<sup>††</sup>P<0.001 for testing the trend.

For trend test, log-transformed AST, ALT, γ-GPT, UAE, and TG. See Table 3 for abbreviations.

doi:10.1371/journal.pone.0173540.t004

(Table 6). Type 1 pattern was associated with higher HbA1c levels, systolic BP and baPWV. Type 2 pattern was associated with higher HDL-cholesterol levels, triglycerides, AST, γ-GTP levels, and diastolic BP.

## Discussion

This is the first report on the relationship between clustered lifestyle, not a single aspect of lifestyle, and cardio-renal-metabolic parameters in patients with T2DM. Using factor analysis, lifestyle patterns in real daily life can be classified into three factors; morningness-eveningness, sleep quality and depressive state (type 1 pattern), consumption of food, alcohol and cigarettes (type 2 pattern), and physical activity (type 3 pattern). Interestingly, each lifestyle is associated with distinct cardio-renal -metabolic parameters.

Subjects with a higher score of type 1 pattern characterized by evening type, poor sleep quality and depressive status showed poor glycemic control and higher ALT and UAE levels in this study. It may be reasonable that these characteristics correlated well with each other because previous reports showed a tendency for such association [14] [15]. These individuals tend to have later dinners, frequent late evening snacks, and less frequent breakfast and consume more food. They were considered to consume a greater amount of their daily energy intake at late time of the day. A previous study demonstrated that late dinnertime increases in postprandial glucose levels after breakfast in the following morning compared to usual dinner time condition through a higher effect of late dinners on carbohydrate digestion and absorption of dietary carbohydrates [30]. Therefore, it seems that late eating could result in worsening of glycaemic control. In addition, consistent with our findings, evening type was shown to be related to more depressive symptoms [31]. Depressive status may also negatively affect glucose metabolism through increased counter-regulatory hormones [19].

Subjects with a higher score of type 1 pattern were more likely to be employed as workers, with higher frequency of overtime work beyond 21:00 PM (data not shown). Such workers may be often forced to stay awake through social cues against their preference. This may lead to disruption of the circadian system. A previous study demonstrated that forced circadian misalignment developed insulin resistance [32]. Therefore, circadian misalignment by environmental elements may contribute to worsening of glycemic control in those patients.

Patients with T2DM are known to have sleep abnormalities compared with healthy subjects [33]. In the present study, subjects with a higher score of type 1 pattern had poor sleep quality and short sleep duration. Recent studies reported both sleep quality and/or duration have negative influence on glucose and lipid metabolism in T2DM patients [9–11]. Sleep has major

**Table 5. Characteristics according to quintile categories of type 3 life style pattern score.**

| Variable                               | Quintile 1          | Quintile 2          | Quintile 3          | Quintile 4          | Quintile 5          | Est    | Est1   | Est2   |
|--|---------------------|---------------------|---------------------|---------------------|---------------------|--------|--------|--------|
| MEQ                                    | 53.6 ± 7.6          | 56.2 ± 6.2          | 58.5 ± 7.1          | 59.7 ± 6.7          | 59.1 ± 7.2          | 1.44¶  | 1.31¶  | 1.30¶  |
| PSQI                                   | 4.4 ± 2.4           | 4.7 ± 2.6           | 5.4 ± 2.9           | 5.6 ± 3.2           | 5.5 ± 3.7           | 0.32¶  | 0.32¶  | 0.35¶  |
| BDI                                    | 10.0 ± 7.5          | 10.0 ± 7.7          | 9.9 ± 7.3           | 9.0 ± 7.1           | 10.5 ± 8.7          | 0.00   | 0.03   | 0.04   |
| Energy intake (kcal/day)               | 1354 ± 391          | 1538 ± 370          | 1680 ± 390          | 1968 ± 559          | 2022 ± 797          | 176.6¶ | 179.8¶ | 180.4¶ |
| Smoking (number)                       | 655 ± 636           | 300 ± 392           | 208 ± 329           | 255 ± 559           | 252 ± 323           | -85.2¶ | -85.8¶ | -85.5¶ |
| Alcohol (g/day)                        | 8.9 ± 21.6          | 10.7 ± 19.6         | 11.0 ± 19.6         | 13.0 ± 23.9         | 13.6 ± 22.7         | 0.44   | 0.54   | 0.57   |
| Physical activity (Mets·h/week)        | 8.9 ± 10.3          | 12.6 ± 11.9         | 19.2 ± 16.2         | 35.8 ± 24.4         | 138.1 ± 110.3       | 28.17¶ | 28.22¶ | 28.08¶ |
| Age (years)                            | 56.8 ± 8.4          | 56.9 ± 9.0          | 57.7 ± 8.1          | 58.6 ± 8.4          | 58.7 ± 8.9          | 0.56*  | -      | -      |
| Gender male (%)                        | 102 (70.8)          | 80 (55.6)           | 91 (63.2)           | 86 (61.1)           | 90 (62.5)           | -0.05  | -      | -      |
| Body mass index (kg/m <sup>2</sup> )   | 25.1 ± 4.2          | 24.6 ± 4.2          | 24.8 ± 4.1          | 24.8 ± 4.2          | 24.0 ± 3.6          | -0.21* | -0.12  | -      |
| Estimated duration of diabetes (years) | 9.4±6.1             | 10.1±7.2            | 9.4±7.0             | 10.3±8.0            | 10.5±7.6            | 0.24   | 0.12   | 0.10   |
| Anti-diabetes medications (yes)        | 127(88.2)           | 125(86.8)           | 120(83.3)           | 118(81.9)           | 126(87.5)           | -0.05  | -0.05  | -0.05  |
| Anti-hypertensives (yes)               | 78(54.2)            | 67(46.5)            | 67(46.5)            | 77(53.5)            | 55(38.2)            | -0.10  | -0.11* | -0.10  |
| Lipid-lowering medications (yes)       | 87(60.4)            | 87(60.4)            | 91(63.2)            | 88(61.1)            | 87(60.4)            | 0.00   | -0.01  | -0.01  |
| Working (yes)                          | 113(78.5)           | 107(74.3)           | 98(68.1)            | 102(70.8)           | 109(75.7)           | -0.05  | 0.04   | 0.04   |
| Shift worker (yes)                     | 15(10.4)            | 10(6.9)             | 13(9.0)             | 18(12.5)            | 21(14.6)            | 0.15   | 0.18*  | 0.18*  |
| Sleep duration (hours)                 | 6.6±1.2             | 6.6±1.1             | 6.4±1.1             | 6.3±1.2             | 6.4±1.3             | -0.07* | -0.08† | -0.08† |
| Wake time, A.M.                        | 6:00[5:30,6:50]     | 6:00[5:30,6:30]     | 6:00[5:13,6:30]     | 6:00[5:30,6:30]     | 5:55[5:00,6:23]     | -0.10† | -0.10* | -0.09* |
| Bed time, P.M.                         | 23:15 [22:30,24:20] | 23:00 [22:20,24:00] | 23:00 [22:08,23:45] | 23:00 [22:00,23:50] | 22:30 [22:00,23:30] | -0.16¶ | -0.13¶ | -0.13¶ |
| Breakfast time, A.M.                   | 7:00[6:30,8:00]     | 7:00[6:30,7:30]     | 7:00[6:30,7:30]     | 7:00[6:30,7:30]     | 7:00[6:25,7:30]     | -0.04  | -0.05  | -0.04  |
| Dinner time, P.M.                      | 19:30 [19:00,20:00] | 19:00 [18:30,20:00] | 19:00 [18:30,19:30] | 19:00 [18:30,20:00] | 19:00 [18:30,19:30] | -0.08† | -0.06* | -0.06* |
| Number of breakfasts (/week)           | 6.2±1.8             | 6.7±0.8             | 6.7±1.1             | 6.7±1.1             | 6.6±1.3             | 0.08*  | 0.06   | 0.06   |
| Late evening snack (yes)               | 60(41.7)            | 59(41.0)            | 53(36.8)            | 58(40.3)            | 58(40.3)            | -0.01  | -0.02  | -0.02  |
| AST (U/L)                              | 20 [17,26]          | 20 [17,27]          | 21 [18,26]          | 22 [19,27]          | 23 [19,27]          | 0.03†  | 0.03†  | 0.03†  |
| ALT (U/L)                              | 21 [16,33]          | 21 [16,29]          | 24 [17,35]          | 23 [17,34]          | 24 [16,33]          | 0.02   | 0.03*  | 0.04†  |
| γ-GTP (U/L)                            | 26 [18,43]          | 26 [17,38]          | 26 [17,43]          | 25 [18,36]          | 25 [16,38]          | -0.03  | -0.02  | -0.01  |
| Uric Acid (mg/dl)                      | 5.8 ± 1.2           | 5.3 ± 1.3           | 5.5 ± 1.3           | 5.5 ± 1.2           | 5.3 ± 1.1           | -0.09† | -0.07* | -0.06* |
| eGFR (ml/min/ 1.73 m <sup>2</sup> )    | 79 ± 18             | 79 ± 17             | 78 ± 19             | 76 ± 16             | 78 ± 18             | -0.48  | -      | 0.37   |
| Total cholesterol (mg/dl)              | 182 ± 28            | 187 ± 27            | 186 ± 27            | 187 ± 29            | 184 ± 29            | 0.48   | 0.35   | 0.41   |
| HDL-C (mg/dl)                          | 57 ± 14             | 60 ± 13             | 57 ± 14             | 60 ± 13             | 62 ± 15             | 0.87¶  | 0.63   | 0.53   |
| Triglycerides (mg/dl)                  | 102 [81, 157]       | 97 [67, 162]        | 105 [71, 153]       | 100 [67, 145]       | 97 [66, 149]        | -0.03* | -0.03  | -0.02  |
| Fasting blood glucose (mg/dl)          | 133 ± 32            | 135 ± 33            | 137 ± 32            | 131 ± 29            | 133 ± 29            | -0.48  | -0.13  | -0.08  |
| HbA1c (%)                              | 6.9 ± 1.0           | 7.0 ± 1.0           | 7.0 ± 1.0           | 6.9 ± 1.0           | 7.0 ± 0.9           | 0.00   | 0.01   | 0.01   |
| HbA1c (mmol/mol)                       | 52.0±11.0           | 53.2±11.3           | 52.7±11.2           | 52.1±11.0           | 52.6±9.7            |        |        |        |
| Systolic BP (mmHg)                     | 127 ± 15            | 127 ± 15            | 125 ± 13            | 127 ± 13            | 126 ± 15            | -0.23  | -0.28  | -0.15  |
| Diastolic BP (mmHg)                    | 79 ± 10             | 78 ± 11             | 77 ± 11             | 77 ± 13             | 75 ± 11             | -0.72* | -0.52  | -0.45  |
| UAE (mg/g creatinine)                  | 10 [6, 24]          | 10 [6, 22]          | 10 [5, 25]          | 10 [6, 21]          | 10 [6, 21]          | -0.03  | -0.03  | -0.02  |

(Continued)

Table 5. (Continued)

| Variable     | Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | Est   | Est1  | Est2  |
|--------------|------------|------------|------------|------------|------------|-------|-------|-------|
| baPWV (cm/s) | 1568 ± 317 | 1523 ± 278 | 1532 ± 280 | 1539 ± 266 | 1554 ± 255 | -1.22 | -8.18 | -8.39 |

Data are mean±SD, median [range: 25% to 75%] or number of subjects (proportion) before adjustment. Est1: Trend estimation for linear trends across quintiles is based on linear regression analysis for continuous variables or logistic regression analysis for categorical variables. Est2: Trend estimation for linear trends across quintiles is based on linear regression analysis for continuous variables or logistic regression analysis for categorical variables adjusted for age and gender. Est3: Trend estimation for linear trends across quintiles is based on linear regression analysis for continuous variables or logistic regression analysis for categorical variables adjusted for age, gender and BMI. eGFR is adjusted for BMI.

\*P<0.05,

†P<0.01,

‡P<0.001 for testing the trend.

For trend test, log-transformed AST, ALT, γ-GTP, UAE, and TG. See Table 3 for abbreviations.

doi:10.1371/journal.pone.0173540.t005

regulatory effects on metabolic function, hormone release and sympathovagal activity. Indeed, sleep deprivation is reported to be associated with low levels of circulating satiety hormone leptin, high levels of appetite stimulating hormone ghrelin [34] and high sympathetic activity [35]. These changes are expected to be deleterious for glycaemic control. Taken together, our findings suggest the synergistic deleterious effects of these unfavourable traits on glycemic control in patients with T2DM. In fact, our multivariate regression analysis suggested that type 1 pattern was associated with higher HbA1c levels even considering other lifestyle patterns. Thus, optimizing these unfavourable habits should be investigated as an intervention to improve glucose control in patients with T2DM.

Subjects with a higher score of type 1 pattern had high UAE levels. The high levels of UAE could be due to poor glycemic control and potentially high sympathetic activity. Due to the presence of accumulated risk factors for atherosclerosis, type 1 pattern was associated with increased atrial stiffness in the multivariate regression model.

Subjects with a high score of type 2 pattern reported high consumption of food, alcohol and cigarettes. Especially, they had high γ-GTP, uric acid, and triglyceride levels. These findings suggest the presence of alcohol-related metabolic dysfunctions. Also, the results of the multivariate regression analysis supported these findings. It is also plausible that the high BP found in these patients was due to the high consumption of alcohol and cigarette [36].

In general, subjects preferring eveningness have been shown to make a custom of adverse health behaviors such as smoking, alcohol use, and physical inactivity compared to those preferring morningness in the general population [37]. In contrast, subjects with a high score of type 2 pattern showed morning type despite having unfavourable habits such as high consumption of alcohol and cigarettes. The exact reason(s) for this discrepancy is (are) not clear at present. However, short sleep duration was reported to be associated with high alcohol consumption [38]. In this study, subjects with a high score of this pattern reported short sleep duration. The latter could adversely affect the classification of morningness-eveningness.

Our study also identified a unique clustered lifestyle characterized by physical activity. The results of multivariate adjusted model demonstrated no correlation with the beneficial cardio-renal-metabolic parameters in subjects with a high score of this pattern, except uric acid. Rather, these subjects had high AST and ALT levels. This is possibly because higher consumption of food could cancel the beneficial effects of habitual physical activity on cardio-renal metabolic parameters. These data suggest the presence of antagonistic effect of lifestyle patterns that tend to accumulate in real daily life on cardio-renal-metabolic parameters.

**Table 6. Multivariate regression analysis adjusted for age, gender and BMI.**

| Variable   | Lifestyle pattern | Standrized regression coefficient | P value |
|--|-------------------|-----------------------------------|---------|
| AST (U/L) (logarithmic transformation)             | type 1            | -0.15                             | 0.88    |
|  | type 2            | 2.37                              | 0.018   |
|  | type 3            | 1.63                              | 0.1     |
| ALT (U/L) (log) (logarithmic transformation)       | type 1            | 1.45                              | 0.15    |
|  | type 2            | -0.17                             | 0.86    |
|  | type 3            | 1.91                              | 0.057   |
| $\gamma$ -GTP (U/L) (logarithmic transformation)   | type 1            | 0.16                              | 0.88    |
|  | type 2            | 5.30                              | <0.001  |
|  | type 3            | -1.09                             | 0.28    |
| Uric Acid (mg/dl)                                  | type 1            | 0.15                              | 0.88    |
|  | type 2            | 1.32                              | 0.19    |
|  | type 3            | -1.48                             | 0.14    |
| Total cholesterol (mg/dl)                          | type 1            | -0.23                             | 0.82    |
|  | type 2            | 0.17                              | 0.86    |
|  | type 3            | 0.98                              | 0.33    |
| HDL-C (mg/dl)                                      | type 1            | -0.31                             | 0.75    |
|  | type 2            | 3.71                              | <0.001  |
|  | type 3            | 0.86                              | 0.39    |
| Triglycerides (mg/dl) (logarithmic transformation) | type 1            | 0.90                              | 0.37    |
|  | type 2            | 1.98                              | 0.048   |
|  | type 3            | -0.78                             | 0.44    |
| HbA1c (%)  | type 1            | 2.39                              | 0.017   |
|  | type 2            | -1.13                             | 0.26    |
|  | type 3            | 0.77                              | 0.44    |
| Systolic BP (mmHg)                                 | type 1            | 2.17                              | 0.03    |
|  | type 2            | 1.72                              | 0.086   |
|  | type 3            | -0.10                             | 0.92    |
| Diastolic BP (mmHg)                                | type 1            | 0.73                              | 0.47    |
|  | type 2            | 2.22                              | 0.027   |
|  | type 3            | -0.82                             | 0.41    |
| UAE (mg/g creatinine) (logarithmic transformation) | type 1            | 0.87                              | 0.38    |
|  | type 2            | 1.44                              | 0.15    |
|  | type 3            | 0.26                              | 0.79    |
| baPWV (cm/s)                                       | type 1            | 1.99                              | 0.047   |
|  | type 2            | 0.59                              | 0.55    |
|  | type 3            | -1.09                             | 0.28    |

See [Table 3](#) for abbreviations.

doi:10.1371/journal.pone.0173540.t006

The present study has certain limitation. First, the cross-sectional design does not allow inference of causal relationship between lifestyle patterns and cardio-renal-metabolic parameters. Also, we could not exclude the possibility that subjects change their daily lifestyles at other periods. Second, we did not confirm the validity and reproducibility of the lifestyle patterns found in this study in a different Japanese population. In this regard, we assessed the validity and reproducibility of the lifestyle patterns in this study by the following steps: 1) Subjects data in this study were randomly divided into two datasets (test and validation

groups) in half, 2) The lifestyle patterns were evaluated by factor analysis in each dataset, and 3) Steps 1) and 2) were repeated ten times. According to this analysis, the lifestyle patterns evaluated by factor analysis in test and validation groups were similar, and the results were almost identical to those in the whole population (data not shown), suggesting that validity and reproducibility of the lifestyle patterns were relatively high in an internal. Finally, there may be other lifestyle patterns that should be considered, although based on the results of previous reports, we chose the possible lifestyle factors related to cardio-renal—metabolic parameters such as sleep quality [10,39], morningness-eveningness trait [14,40,41], depression status [17,18], energy intake and physical activity [3–5], smoking [42] and alcohol consumption [43].

## Conclusions

The present study identified three clustering of lifestyle patterns and confirmed the relationship between such patterns and cardio-renal-metabolic parameters in T2DM patients free of history of CVD. The results highlight the importance of intervention to modifiable lifestyles based on their complex lifestyle pattern in daily life, in order to achieve appropriate cardio-renal-metabolic functions and prevent future CVD in patients with T2DM.

## Acknowledgments

The authors thank the following staff who participated in this trial, including Mses Risa Yamamoto and Emi Ito (Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine), Satako Douguchi, Chiyoko Sato, Yoko Ono, Norie Shiina, Nana Shiozawa, Mariko Kobori, Misato Ojima, Akiko Haginoya, and Kumiko Fujisaku, and Messrs Tadanori Koibuchi and Katuhiro Kawauchi (Naka Memorial Clinic) for the excellent technical support.

## Author Contributions

**Conceptualization:** T. Ogihara TM YO T. Osonoi MS AT SN YS HI MG AK HW.

**Data curation:** T. Ogihara TM YO YS MG HW.

**Formal analysis:** MG.

**Funding acquisition:** TM HW.

**Investigation:** T. Ogihara TM YO T. Osonoi MS AT SN YS HI MG AK HW.

**Methodology:** TM YO HW.

**Project administration:** TM HW.

**Resources:** T. Ogihara TM YO T. Osonoi MS AT SN YS HI MG AK HW.

**Software:** MG.

**Supervision:** TM HW.

**Validation:** TM HW.

**Visualization:** T. Ogihara TM YO T. Osonoi MS AT SN YS HI MG AK HW.

**Writing – original draft:** T. Ogihara TM.

**Writing – review & editing:** YO T. Osonoi MS AT SN YS HI MG AK HW.

## References

1. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study G (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). *Clin Sci (Lond)* 101: 671–679.
2. Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyorala K, et al. (2004) Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. *Diabetologia* 47: 2118–2128. doi: [10.1007/s00125-004-1574-5](https://doi.org/10.1007/s00125-004-1574-5) PMID: [15662552](https://pubmed.ncbi.nlm.nih.gov/15662552/)
3. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 346: 393–403. doi: [10.1056/NEJMoa012512](https://doi.org/10.1056/NEJMoa012512) PMID: [11832527](https://pubmed.ncbi.nlm.nih.gov/11832527/)
4. Sone H, Tanaka S, Imuro S, Tanaka S, Oida K, Yamasaki Y, et al. (2010) Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). *Diabetologia* 53: 419–428. doi: [10.1007/s00125-009-1622-2](https://doi.org/10.1007/s00125-009-1622-2) PMID: [20054522](https://pubmed.ncbi.nlm.nih.gov/20054522/)
5. Hu G, Jousilahti P, Barengo NC, Qiao Q, Lakka TA, Tuomilehto J (2005) Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes. *Diabetes Care* 28: 799–805. PMID: [15793176](https://pubmed.ncbi.nlm.nih.gov/15793176/)
6. Look ARG, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med* 369: 145–154. doi: [10.1056/NEJMoa1212914](https://doi.org/10.1056/NEJMoa1212914) PMID: [23796131](https://pubmed.ncbi.nlm.nih.gov/23796131/)
7. Yaggi HK, Araujo AB, McKinlay JB (2006) Sleep duration as a risk factor for the development of type 2 diabetes. *Diabetes Care* 29: 657–661. PMID: [16505522](https://pubmed.ncbi.nlm.nih.gov/16505522/)
8. Ayas NT, White DP, Manson JE, Stampfer MJ, Speizer FE, Malhotra A, et al. (2003) A prospective study of sleep duration and coronary heart disease in women. *Arch Intern Med* 163: 205–209. PMID: [12546611](https://pubmed.ncbi.nlm.nih.gov/12546611/)
9. Williams CJ, Hu FB, Patel SR, Mantzoros CS (2007) Sleep duration and snoring in relation to biomarkers of cardiovascular disease risk among women with type 2 diabetes. *Diabetes Care* 30: 1233–1240. doi: [10.2337/dc06-2107](https://doi.org/10.2337/dc06-2107) PMID: [17322482](https://pubmed.ncbi.nlm.nih.gov/17322482/)
10. Knutson KL, Ryden AM, Mander BA, Van Cauter E (2006) Role of sleep duration and quality in the risk and severity of type 2 diabetes mellitus. *Arch Intern Med* 166: 1768–1774. doi: [10.1001/archinte.166.16.1768](https://doi.org/10.1001/archinte.166.16.1768) PMID: [16983057](https://pubmed.ncbi.nlm.nih.gov/16983057/)
11. Wan Mahmood WA, Draman Yusoff MS, Behan LA, Di Perna A, Kyaw Tun T, McDermott J, et al. (2013) Association between Sleep Disruption and Levels of Lipids in Caucasians with Type 2 Diabetes. *Int J Endocrinol* 2013: 341506. doi: [10.1155/2013/341506](https://doi.org/10.1155/2013/341506) PMID: [24072996](https://pubmed.ncbi.nlm.nih.gov/24072996/)
12. Broms U, Kaprio J, Hublin C, Partinen M, Madden PA, Koskenvuo M (2011) Evening types are more often current smokers and nicotine-dependent—a study of Finnish adult twins. *Addiction* 106: 170–177. doi: [10.1111/j.1360-0443.2010.03112.x](https://doi.org/10.1111/j.1360-0443.2010.03112.x) PMID: [20883457](https://pubmed.ncbi.nlm.nih.gov/20883457/)
13. Ostberg O (1973) Circadian rhythms of food intake and oral temperature in "morning" and "evening" groups of individuals. *Ergonomics* 16: 203–209. doi: [10.1080/00140137308924497](https://doi.org/10.1080/00140137308924497) PMID: [4726654](https://pubmed.ncbi.nlm.nih.gov/4726654/)
14. Iwasaki M, Hirose T, Mita T, Sato F, Ito C, Yamamoto R, et al. (2013) Morningness-eveningness questionnaire score correlates with glycated hemoglobin in middle-aged male workers with type 2 diabetes mellitus. *Morningness*. *J Diabetes Investig* 4: 376–381. doi: [10.1111/jdi.12047](https://doi.org/10.1111/jdi.12047) PMID: [24843683](https://pubmed.ncbi.nlm.nih.gov/24843683/)
15. Osonoi Y, Mita T, Osonoi T, Saito M, Tamasawa A, Nakayama S, et al. (2014) Morningness-eveningness questionnaire score and metabolic parameters in patients with type 2 diabetes mellitus. *Chronobiol Int* 31: 1017–1023. doi: [10.3109/07420528.2014.943843](https://doi.org/10.3109/07420528.2014.943843) PMID: [25102425](https://pubmed.ncbi.nlm.nih.gov/25102425/)
16. Lin EH, Katon W, Von Korff M, Rutter C, Simon GE, Oliver M, et al. (2004) Relationship of depression and diabetes self-care, medication adherence, and preventive care. *Diabetes Care* 27: 2154–2160. PMID: [15333477](https://pubmed.ncbi.nlm.nih.gov/15333477/)
17. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE (2000) Depression and poor glycemic control: a meta-analytic review of the literature. *Diabetes Care* 23: 934–942. PMID: [10895843](https://pubmed.ncbi.nlm.nih.gov/10895843/)
18. de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ (2001) Association of depression and diabetes complications: a meta-analysis. *Psychosom Med* 63: 619–630. PMID: [11485116](https://pubmed.ncbi.nlm.nih.gov/11485116/)
19. Musselman DL, Betan E, Larsen H, Phillips LS (2003) Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. *Biol Psychiatry* 54: 317–329. PMID: [12893107](https://pubmed.ncbi.nlm.nih.gov/12893107/)
20. Nakamura M, Yamashita T, Yajima J, Oikawa Y, Sagara K, Koike A, et al. Brachial-ankle pulse wave velocity as a risk stratification index for the short-term prognosis of type 2 diabetic patients with coronary artery disease. *Hypertens Res* 33: 1018–1024. doi: [10.1038/hr.2010.126](https://doi.org/10.1038/hr.2010.126) PMID: [20703233](https://pubmed.ncbi.nlm.nih.gov/20703233/)

21. Osonoi Y, Mita T, Osonoi T, Saito M, Tamasawa A, Nakayama S, et al. (2015) Poor sleep quality is associated with increased arterial stiffness in Japanese patients with type 2 diabetes mellitus. *BMC Endocr Disord* 15: 29. doi: [10.1186/s12902-015-0026-1](https://doi.org/10.1186/s12902-015-0026-1) PMID: [26084960](https://pubmed.ncbi.nlm.nih.gov/26084960/)
22. Osonoi Y, Mita T, Osonoi T, Saito M, Tamasawa A, Nakayama S, et al. (2016) Relationship between dietary patterns and risk factors for cardiovascular disease in patients with type 2 diabetes mellitus: a cross-sectional study. *Nutr J* 15: 15. doi: [10.1186/s12937-016-0132-6](https://doi.org/10.1186/s12937-016-0132-6) PMID: [26847556](https://pubmed.ncbi.nlm.nih.gov/26847556/)
23. Hone JA, Ostberg O (1976) A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. *Int J Chronobiol* 4: 97–110. PMID: [1027738](https://pubmed.ncbi.nlm.nih.gov/1027738/)
24. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 28: 193–213. PMID: [2748771](https://pubmed.ncbi.nlm.nih.gov/2748771/)
25. Beck AT, Steer RA, Brown GK (1996) *Manual for the Beck Depression Inventory-II*. San Antonio, TX: Psychological Corporation.
26. Agency SaT (2005) *Standard Tables of Food Composition in Japan (in Japanese)*. Tokyo. Printing Bureau of the Ministry of Finance: 5th rev ed.
27. Craig CL, Marshall AL, Sjoström M, Bauman AE, Booth ML, Ainsworth BE, et al. (2003) International physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc* 35: 1381–1395. doi: [10.1249/01.MSS.0000078924.61453.FB](https://doi.org/10.1249/01.MSS.0000078924.61453.FB) PMID: [12900694](https://pubmed.ncbi.nlm.nih.gov/12900694/)
28. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis* 53: 982–992. doi: [10.1053/j.ajkd.2008.12.034](https://doi.org/10.1053/j.ajkd.2008.12.034) PMID: [19339088](https://pubmed.ncbi.nlm.nih.gov/19339088/)
29. Takeno K, Mita T, Nakayama S, Goto H, Komiya K, Abe H, et al. (2012) Masked hypertension, endothelial dysfunction, and arterial stiffness in type 2 diabetes mellitus: a pilot study. *Am J Hypertens* 25: 165–170. doi: [10.1038/ajh.2011.158](https://doi.org/10.1038/ajh.2011.158) PMID: [22089111](https://pubmed.ncbi.nlm.nih.gov/22089111/)
30. Tsuchida Y, Hata S, Sone Y (2013) Effects of a late supper on digestion and the absorption of dietary carbohydrates in the following morning. *J Physiol Anthropol* 32: 9. doi: [10.1186/1880-6805-32-9](https://doi.org/10.1186/1880-6805-32-9) PMID: [23705984](https://pubmed.ncbi.nlm.nih.gov/23705984/)
31. Roeser K, Obergfell F, Meule A, Vogele C, Schlarb AA, Kubler A (2012) Of larks and hearts—morningness/eveningness, heart rate variability and cardiovascular stress response at different times of day. *Physiol Behav* 106: 151–157. doi: [10.1016/j.physbeh.2012.01.023](https://doi.org/10.1016/j.physbeh.2012.01.023) PMID: [22330324](https://pubmed.ncbi.nlm.nih.gov/22330324/)
32. Scheer FA, Hilton MF, Mantzoros CS, Shea SA (2009) Adverse metabolic and cardiovascular consequences of circadian misalignment. *Proc Natl Acad Sci U S A* 106: 4453–4458. doi: [10.1073/pnas.0808180106](https://doi.org/10.1073/pnas.0808180106) PMID: [19255424](https://pubmed.ncbi.nlm.nih.gov/19255424/)
33. Trento M, Broglio F, Riganti F, Basile M, Borgo E, Kucich C, et al. (2008) Sleep abnormalities in type 2 diabetes may be associated with glycemic control. *Acta Diabetol* 45: 225–229. doi: [10.1007/s00592-008-0047-6](https://doi.org/10.1007/s00592-008-0047-6) PMID: [18685806](https://pubmed.ncbi.nlm.nih.gov/18685806/)
34. Spiegel K, Tasali E, Penev P, Van Cauter E (2004) Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. *Ann Intern Med* 141: 846–850. PMID: [15583226](https://pubmed.ncbi.nlm.nih.gov/15583226/)
35. Vgontzas AN, Mastorakos G, Bixler EO, Kales A, Gold PW, Chrousos GP (1999) Sleep deprivation effects on the activity of the hypothalamic-pituitary-adrenal and growth axes: potential clinical implications. *Clin Endocrinol (Oxf)* 51: 205–215.
36. Jin Z, Xiang C, Cai Q, Wei X, He J (2013) Alcohol consumption as a preventive factor for developing rheumatoid arthritis: a dose-response meta-analysis of prospective studies. *Ann Rheum Dis*.
37. Adan A (1994) Chronotype and personality factors in the daily consumption of alcohol and psychostimulants. *Addiction* 89: 455–462. PMID: [8025504](https://pubmed.ncbi.nlm.nih.gov/8025504/)
38. Chaput JP, McNeil J, Despres JP, Bouchard C, Tremblay A (2012) Short sleep duration is associated with greater alcohol consumption in adults. *Appetite* 59: 650–655. doi: [10.1016/j.appet.2012.07.012](https://doi.org/10.1016/j.appet.2012.07.012) PMID: [22841812](https://pubmed.ncbi.nlm.nih.gov/22841812/)
39. Ohkuma T, Fujii H, Iwase M, Kikuchi Y, Ogata S, Idewaki Y, et al. (2013) Impact of sleep duration on obesity and the glycemic level in patients with type 2 diabetes: the Fukuoka Diabetes Registry. *Diabetes Care* 36: 611–617. doi: [10.2337/dc12-0904](https://doi.org/10.2337/dc12-0904) PMID: [23150286](https://pubmed.ncbi.nlm.nih.gov/23150286/)
40. Lee JH, Kim SJ, Lee SY, Jang KH, Kim IS, Duffy JF (2014) Reliability and validity of the Korean version of Morningness-Eveningness Questionnaire in adults aged 20–39 years. *Chronobiol Int* 31: 479–486. doi: [10.3109/07420528.2013.867864](https://doi.org/10.3109/07420528.2013.867864) PMID: [24467306](https://pubmed.ncbi.nlm.nih.gov/24467306/)
41. Reutrakul S, Hood MM, Crowley SJ, Morgan MK, Teodori M, Knutson KL, et al. (2013) Chronotype is independently associated with glycemic control in type 2 diabetes. *Diabetes Care* 36: 2523–2529. doi: [10.2337/dc12-2697](https://doi.org/10.2337/dc12-2697) PMID: [23637357](https://pubmed.ncbi.nlm.nih.gov/23637357/)



42. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J (2007) Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA* 298: 2654–2664. doi: [10.1001/jama.298.22.2654](https://doi.org/10.1001/jama.298.22.2654) PMID: [18073361](https://pubmed.ncbi.nlm.nih.gov/18073361/)
43. Seike N, Noda M, Kadowaki T (2008) Alcohol consumption and risk of type 2 diabetes mellitus in Japanese: a systematic review. *Asia Pac J Clin Nutr* 17: 545–551. PMID: [19114388](https://pubmed.ncbi.nlm.nih.gov/19114388/)